Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Chief Financial Officer | February 28, 2019 | March 01, 2019 |
| ARENA PHARMACEUTICALS INCARNA · Entity 94856 | Director | June 17, 2020 | June 18, 2020 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · COO and CFO | June 04, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date February 28, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2029-02-27 | Direct | 20,000 |
Reported balance
After 2019-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests
F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
ARENA PHARMACEUTICALS INC
Report date June 17, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,902 |
Reported balance
After 2020-06-17 transaction · row 1
1 source rowRow 1 · 2020-06-17 · Sale · Disposed 304 · Balance 5,902 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
Summit Therapeutics Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,123,603 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Purchase · Acquired 25,000 · Balance 3,098,603 Row 2 · 2026-06-04 · Purchase · Acquired 25,000 · Balance 3,123,603 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 3,273 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.47 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 550,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 7,937 · Balance 0 F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
F2: Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017.
F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes.
REATA PHARMACEUTICALS INC
Report date September 26, 2023 · Filed September 26, 2023
Section 16 reporting ended · disclosed 2023-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 1
1 source rowRow 1 · 2023-09-26 · Disposition to issuer · Disposed 62,621 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.29 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-26 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.32 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-26 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.15 · Expires 2032-03-16 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-26 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.71 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-26 · Disposition to issuer · Disposed 95,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.70 · Expires 2029-08-28 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-26 · Disposition to issuer · Disposed 175,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.79 · Expires 2029-08-28 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $207.20 · Expires 2030-01-02 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-26 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)
F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020715 · rdgdoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 20:40 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 25,000 | $14.43 | $360,750.00 |
DisclosureSEC source: 0001569769-26-000004 · wk-form4_1780605646.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,123,603 Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 20:40 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 25,000 | $14.46 | $361,500.00 |
DisclosureSEC source: 0001569769-26-000004 · wk-form4_1780605646.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,098,603 Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:10 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 53,361 | $18.74 | $999,985.14 |
DisclosureSEC source: 0001569769-25-000002 · wk-form4_1761250212.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,073,603 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:13 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027392 · rdgdoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:13 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 11,200,000 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-25-000095 · wk-form4_1746137627.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,200,000 Underlying: Common Stock · 11,200,000 shares Expires 2033-10-13 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 21:29 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 44,052 | $22.70 | $999,980.40 |
DisclosureSEC source: 0001599298-24-000136 · wk-form4_1726262933.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,020,242 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 20:44 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantPerformance Stock Option (right to buy) · Derivative | 2,800,000 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-24-000125 · wk-form4_1724445873.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,800,000 Underlying: Common Stock · 2,800,000 shares Expires 2033-10-13 F2 · price: Not applicable. F1 · derivative.exercise_date: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 11,200,000 shares underlying options which were granted on October 13, 2023 that remain subject to the satisfaction of performance conditions. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 22:53 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001437749-24-026500 · rdgdoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-08-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on the date of the Issuer's next annual meeting of stockholders and the remaining shares will vest on a monthly basis over three years thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:35 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021127 · rdgdoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 6, 2024. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 21:52 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 1,100,000 | Not disclosed Strike: $3.85 | Not disclosed |
DisclosureSEC source: 0001599298-24-000060 · wk-form4_1712267527.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 1,100,000 shares Expires 2034-04-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on April 2, 2024. The shares underlying the option shall vest in four equal annual installments. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 20:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 14,000,000 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001569769-23-000007 · wk-form4_1697486782.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000,000 Underlying: Common Stock · 14,000,000 shares Expires 2033-10-13 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 14,000,000 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 20:06 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 2,976,190 | $1.68 | $4,999,999.20 |
DisclosureSEC source: 0001569769-23-000007 · wk-form4_1697486782.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,976,190 F1 · shares: The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68. F1 · balance_after: The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $207.20 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 8 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 25,000 shares Expires 2030-01-02 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $104.79 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 7 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 50,000 shares Expires 2029-08-28 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 175,000 | Not disclosed Strike: $72.70 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 6 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 175,000 shares Expires 2029-08-28 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 95,475 | Not disclosed Strike: $36.71 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 5 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 95,475 shares Expires 2033-01-03 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $34.15 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 75,000 shares Expires 2032-03-16 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $27.32 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 75,000 shares Expires 2032-01-03 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $121.29 | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 24,000 shares Expires 2031-01-04 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · derivative.exercise_date: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| September 26, 2023 Filed Sep 26, 2023 16:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Disposition to issuerClass A common stock | 62,621 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019540 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 16:43 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 1,755 | $168.41 | $295,565.69 |
DisclosureSEC source: 0001209191-23-046306 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,621 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $168.3565 to $168.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044009 · doc4.xml · derivative · entry 5 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 75,000 | $72.70 | $5,452,500.00 |
DisclosureSEC source: 0001209191-23-044009 · doc4.xml · derivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A common stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001209191-23-044009 · doc4.xml · derivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,000 Underlying: Class B common stock · 75,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 250,000 shares, became exercisable as to 62,500 shares on August 28, 2020, with the remainder vesting in twelve equal quarterly installments thereafter, subject to continued service through each vesting date. F1 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 75,000 | $164.62 | $12,346,297.50 |
DisclosureSEC source: 0001209191-23-044009 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,376 F2 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $165.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044009 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 06, 2023 Filed Jul 10, 2023 16:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantClass A common stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041931 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,376 F1 · shares: The shares represent Restricted Stock Units granted with performance criteria (PSUs). On December 17, 2020, the reporting person was granted 6,000 PSUs. On July 6, 2023, based on certain performance criteria, the PSUs vested as to 1,500 shares, with the remainder vesting 1/12th on each subsequent 3 month anniversary, subject to continued service through each vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $27.32 | $0.00 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · derivative · entry 10 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A common stock · 25,000 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 250 | $105.55 | $26,387.50 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 9 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,376 Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 14,016 | $105.05 | $1,472,359.78 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 8 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,626 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $104.515 to $105.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 25,530 | $104.09 | $2,657,397.28 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 7 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,642 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $103.51 to $104.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 3,643 | $102.73 | $374,227.54 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 6 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,172 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $102.4807 to $102.995. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 16,163 | $101.98 | $1,648,378.71 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 5 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,815 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $101.48 to $102.44. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 9,157 | $101.05 | $925,348.73 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,978 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $100.496 to $101.44. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 9,326 | $99.75 | $930,243.32 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,135 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $99.50 to $100.4745. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass A common stock | 25,000 | $27.32 | $683,000.00 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 4,711 | $99.62 | $469,297.10 |
DisclosureSEC source: 0001209191-23-037043 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,461 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $99.50 to $99.92 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 25, 2023 Filed Jun 6, 2023 23:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016810 · rdgdoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023. Read SEC document |
| May 16, 2023 Filed May 17, 2023 16:39 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 625 | $80.93 | $50,583.75 |
DisclosureSEC source: 0001209191-23-030223 · doc4.xml · nonDerivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,172 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| May 15, 2023 Filed May 17, 2023 16:39 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 200 | $85.64 | $17,128.50 |
DisclosureSEC source: 0001209191-23-030223 · doc4.xml · nonDerivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,797 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.635 to $85.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2023 Filed May 17, 2023 16:39 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 8,867 | $84.86 | $752,496.18 |
DisclosureSEC source: 0001209191-23-030223 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,997 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.595 to $85.545. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2023 Filed May 17, 2023 16:39 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 12,440 | $84.32 | $1,048,942.04 |
DisclosureSEC source: 0001209191-23-030223 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,864 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.595 to $84.59 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2023 Filed May 9, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right-to-buy) · Derivative | 50,000 | $0.00 Strike: $104.79 | $0.00 |
DisclosureSEC source: 0001209191-23-028269 · doc4.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class B common stock · 50,000 shares Expires 2029-08-28 F2 · derivative.exercise_date: On August 29, 2019, the reporting person was granted an option to purchase 50,000 shares of Class B common stock subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the option vested as to 50,000 shares. Read SEC document |
| May 05, 2023 Filed May 9, 2023 16:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantClass A common stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028269 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,304 F1 · shares: On August 29, 2019, the reporting person was granted 50,000 Restricted Stock Units subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the 50,000 RSUs vested. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 17:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 622 | $84.70 | $52,680.29 |
DisclosureSEC source: 0001209191-23-017235 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,304 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:48 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 3,587 | $87.97 | $315,548.39 |
DisclosureSEC source: 0001209191-23-016339 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,926 F1 · kind: The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $87.91 to $88.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 16:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right-to-buy) · Derivative | 75,000 | $0.00 Strike: $34.15 | $0.00 |
DisclosureSEC source: 0001209191-23-014095 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A common stock · 75,000 shares Expires 2032-03-16 F1 · derivative.exercise_date: On September 16, 2022, the reporting person was granted an option to purchase 75,000 shares of Class A common stock. On February 28, 2023 based on the satisfaction of certain performance criteria, the option vested as to 14,063 shares and is set to vest 1/16th of the original grant on each three month anniversary such that 100% of the options will be vested on the four-year anniversary of the date of grant, subject to continued service through each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 17:17 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right-to-buy) · Derivative | 95,475 | $0.00 Strike: $36.71 | $0.00 |
DisclosureSEC source: 0001209191-23-001143 · doc4.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,475 Underlying: Class A common stock · 95,475 shares Expires 2033-01-03 F2 · derivative.exercise_date: The options vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 17:17 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantClass A common stock | 23,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001143 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,513 F1 · shares: The shares represent Restricted Stock Units, which vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.